An Open-Label Extension for the Phase 2 Study in Early Symptomatic Amyotrophic Lateral Sclerosis Patients on Stable Background Therapy to Assess Bioenergetic Catalysis With CNM-Au8 to Slow Disease Progression in ALS
Clinical trial NCT05299658 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05299658
- Sponsor
- Clene Nanomedicine
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-11-13
- Primary completion
- 2026-06-01
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.